Innovation Impact Investment advisory group

Dr Sheriff Abdullahi is the Managing Director for Singapore, Malaysia and Brunei at the global biopharmaceutical company, MSD. He is responsible for driving the commercial success of MSD’s human health business in Singapore, Malaysia, and Brunei.

Since joining MSD in 2020, he led global teams to expand access to MSD’s medicines and vaccines around the world, and improved access to MSD’s oncology medicines and vaccines across the world. He also established global centres of excellence within MSD in value-based contracting, innovative financing, and customer partnerships.

Before joining MSD, Sheriff was with GE Healthcare and spent many years as a consultant in the UK, working with clients including the NHS.

He is a leader who seeks curiosity, creativity, and impact from his teams. Sheriff cares deeply about helping others find ways to flourish and takes great pride in celebrating people for who they are and who they want to be.

Sheriff holds an Engineering Doctorate and a Master of Science from Loughborough University in UK. He is married and has three children. Outside of work, he enjoys reading about history and spending quality time with his family.

Connect with Sheriff on LinkedIn.

Rachel joined Macmillan’s board in September 2020. Rachel chairs Macmillan's Impact Investment Committee that oversees our investments in early stage companies delivering innovations in cancer care, chairs our Technology Advisory Committee that oversees the delivery of our technology strategy and serves on our People Committee.

Rachel has a portfolio of non-executive roles, advisory board roles and strategic advisory consultancy on business resilience and digital transformation. Prior to her portfolio career, Rachel enjoyed 30-years in technology leadership in financial services, insurance, telecoms, media and retail.  She held roles at M&S, WPP, BT, Vodafone, ACE Group, HSBC and ABN Amro, living and working across Europe, MENA, Asia, North and Latin America.

She has wide-ranging governance experience from her corporate career and from serving on boards of several charities, advisory and industry bodies over the past 20 years. Rachel currently serves on the Board of GlobalData, the Advisory Boards of PWC, Aldermore Bank and Xiid, and on the UK's Women's Business Council. A passionate EDI champion, Rachel sponsors a number of global development programmes for women and the LGBTQ+ community.

Connect with Rachel on LinkedIn.

Tanya Humphreys brings over 16 years of experience in public, private, and third-sector management, specialising in driving measurable impact and transformational change in healthcare through strategic investments and partnerships. As Macmillan Cancer Support’s former Head of Impact Investments, Tanya led the strategic direction of the charity’s pioneering Innovation Impact Investment Portfolio. Under her leadership, Macmillan closed multiple high-impact deals totalling c. £2 million, fostering innovation to improve cancer care while achieving both social and financial returns.

In addition to her advisory role at Macmillan, Tanya contributes her expertise to organisations such as the Global Impact Investment Network’s Healthcare Knowledge Hub Advisory Committee and Oxfam’s Global Innovation Lab for Equality. She is passionate about evidence-based decision-making and leveraging insights to maximise both social impact and financial returns.

David Kaye is the founder and CEO of Puma Capital Group. He is responsible for leading their strategy to create a robust and dynamic platform on which each of their four core businesses can thrive: Puma Investments, Puma Private Equity, Puma Property Finance and Puma Public Markets.

David graduated from Oxford with a degree in law and practiced as a commercial barrister at a leading London set of chambers for five years. He specialised in advising on a range of complex commercial legal issues with a particular focus on financial investments and real estate. He joined Shore Capital Group, of which Puma Capital Group is a member, in January 2006.

Prior to joining Macmillan’s innovation impact investment advisory group, David was a long-standing volunteer member of the Macmillan Cancer Support Annual Gala committee and chaired the event for several years.

Connect with David on LinkedIn.

Dawn is a cancer survivor. She has lived experience of many of the issues that matter most to cancer and a personal goal to do whatever she can to aid in improving the diagnosis experience of other cancer patients.

In her day job, Dawn is an Associate Professor of Health Economics and Health Policy at the Peninsula Technology Assessment Group (PenTAG). PenTAG is a prestigious research unit in the UK specialising in providing expert advice on the clinical and cost-effectiveness of new diagnostics and treatments to the National Institute of Health and Care Excellence (NICE). Dawn joined PenTAG and Exeter University in September 2022, following a successful tenure as the Chief Scientific Officer at a health economics consultancy Lumanity (previously BresMed). Dawn serves as a member of NICEs Interventional Procedures Advisory Committee (IPAC).

Outside of her day job Dawn volunteers for Citizens Advice.

Connect with Dawn on LinkedIn.

Archie has recently joined Bramble Investments as a Partner. Bramble is an investment firm dedicated to supporting innovative food businesses and capturing a share of the value they create. Previously, he was the Innovation Director at True, a consumer-focused investment and advisory business. Archie supports leading corporates on innovation, strategy, and venture investment activity, and used to lead True’s ESG and Impact initiatives.  

Archie was previously the Head of Business Development and Innovation at the John Lewis Partnership. He started his career across audit and strategy consulting at PwC. He has an MSci in Pharmacology from the University of Bristol and a certification from the University of Cambridge Institute for Sustainability Leadership course. 

Connect with Archie on LinkedIn.

Veronique Morel-Kane is a prominent financial sector expert, holding prestigious roles such as the Branch Principal at Raymond James and past positions like Vice President at Merrill Lynch. A Fellow of the CISI Institute and a Chartered Wealth Manager, she boasts over 20 years of experience.

Recognised for her financial acumen, Veronique is a frequent media contributor and has garnered numerous awards, including Wealth Manager of the Year and awards for Best Client Engagement and Contribution to Wealth for Good (global reach).

Her commitment to diversity is evident through honours like Woman of the Year in Investment Advice. Beyond her professional achievements, Veronique influences the industry as a judge for various investment awards and serves on the investment committee of the RCDOW and the Guild of Investment Managers on the education committee. Her client portfolio spans private individuals, corporations, and charities, in the US and UK, showcasing her exceptional dedication and innovation in finance.

Anas joined Macmillan’s Board of Trustees in February 2025. He is a medical doctor, tech executive and board advisor with over 15 years of expertise at the intersection of healthcare, technology and business leadership. Anas is an active public speaker, a published academic and an advocate for digital health. He has contributed extensively to public health, international humanitarian medicine, and medical education, and has earnt recognition through multiple honours and publications.

Anas is Chief Executive and co-founder of mission-driven Patchwork Health, which has created a modern workforce planning and management platform used by over 100,000 clinicians across the UK. The organisation works closely with the NHS and the product is built by healthcare professionals for healthcare professionals. He has previously held leadership roles in healthcare improvement initiatives, such as the Clinical Innovation and Improvement Fellowship at Chelsea and Westminster Hospital and the Darzi Fellowship in Healthcare Leadership.